Launch of Hepatic Oncology: a journal dedicated to the management of cancers of the liver

319

Hepatic Oncology is published by Future Medicine Ltd, and joins its portfolio of oncology journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

The direction of the journal is led by a team of three senior editors, Jordi Bruix (University of Barcelona, Spain), Richard Finn (University of California, Los Angeles, USA) and Ronnie TP Poon (The University of Hong Kong, Hong Kong), along with an international editorial Board of experts in the field.

Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP2.

Coverage includes:

  • Studies on all types of primary and secondary hepatic cancers
  • Diagnosis, imaging, prognosis and risk factors
  • Pharmacoeconomics, outcomes and comparative effectiveness research
  • Therapy, including surgery, chemotherapy, chemoembolization, ablation, radiotherapy, hormonal and biological therapies
  • Translational research and biomarker studies

Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and paediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy.

Writing in the foreword to the inaugural issue Finn and Bruix stated: “The past decade has brought a robust amount of interest in liver cancer, spanning from bench research to the clinic in all aspects of liver tumour management. Our goal in the development of the journal is to provide a high-impact outlet for basic science, as well as all clinical aspects of liver oncology.”

A press release from Future Medicine Ltd stated that Hepatic Oncology welcomes submissions of original research and reviews. To submit an article proposal or for further information, please email the launch editor Laura Dormer (l.dormer@futuremedicine.com).